Efficacy and safety of perampanel add-on therapy in children with epilepsy of genetic etiology.
10.7499/j.issn.1008-8830.2409069
- Author:
Jia-Qin YI
1
;
Dan SUN
1
Author Information
1. Department of Neurology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China com).
- Publication Type:Journal Article
- Keywords:
Add-on therapy;
Child;
Epilepsy;
Perampanel
- MeSH:
Humans;
Male;
Female;
Nitriles;
Child;
Pyridones/administration & dosage*;
Child, Preschool;
Retrospective Studies;
Anticonvulsants/administration & dosage*;
Epilepsy/etiology*;
Adolescent;
Infant;
Drug Therapy, Combination
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(2):171-175
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the efficacy and safety of perampanel (PER) add-on therapy in children with epilepsy of genetic etiology.
METHODS:A retrospective analysis was conducted on the clinical data of 53 children who attended the Department of Neurology, Wuhan Children's Hospital, from November 2020 to April 2023. All children received PER add-on therapy and were diagnosed with epilepsy of genetic etiology based on whole-exome sequencing. The primary outcome measure was the proportion of children with a reduction in seizure frequency of ≥50% at month 12 of PER treatment (i.e., response rate), and the secondary outcome measures were response rates at months 3 and 6 of treatment. The influencing factors for the efficacy of PER add-on therapy in the treatment of epilepsy of genetic etiology were analyzed, and adverse events were recorded.
RESULTS:The median follow-up duration was 13.10 months. After 12 months of follow-up, 42 children were included in the analysis, comprising 25 boys (60%) and 17 girls (40%). The median initial dose of PER was 1.5 (1.0, 2.0) mg/d, and the median maintenance dose was 4.0 (3.0, 8.0) mg/d. The response rates to PER at months 3, 6, and 12 of treatment were 61% (30/49), 54% (25/46), and 48% (20/42), respectively. No significant difference in the efficacy of PER was observed between children with mutations in genes encoding different protein functions (P>0.05). The most common adverse event reported was fatigue, observed in 3 children (6%).
CONCLUSIONS:PER add-on therapy demonstrates good efficacy and safety in children with epilepsy of genetic etiology. No influencing factors for the efficacy of PER have been identified to date.
